News

Fierce Biotech5h
ALX Oncology doubles down on lead CD47 inhibitor after asset fails two midstage cancer trials
Just over a month after laying off staff to focus on its lead cancer candidate, ALX Oncology announced that the asset ...
Fierce Biotech7h
HHS reverses course, says long-running women’s health study will retain funding
Days after the Women’s Health Initiative, one of the largest and longest women’s health studies in the world, announced that ...
Fierce Biotech7h
Study illustrates pros, cons in AI readings of 3D mammography scans
A retrospective study of an artificial intelligence program for reading 3D mammography scans illustrated the pros, cons and ...
Fierce Biotech10h
FDA puts Vyne in a twist, slapping hold on psoriasis trial over testicular toxicity concerns
Vyne Therapeutics’ attempt to develop a safer, more tolerable BET inhibitor has hit turbulence. | Vyne Therapeutics’ attempt ...
Fierce Biotech8h
M&A remains ‘top priority’ for Big Pharmas in the face of tariff threat
Big Pharmas aren’t letting the looming threat of potential tariffs divert them from their M&A strategies for the year—at ...
Fierce Biotech11h
Chutes & Ladders—Galapagos CEO eyes exit as spinout names leader
The CEO and board chair of Belgian biotech Galapagos has announced plans to leave the islands. Paul Stoffels, M.D., will ...
Fierce Biotech21h
Caribou cuts 32% of staff, further purges pipeline to focus on oncology CAR-T prospects
The pipeline purge comes less than a year after Caribou cut 12% of staff and ended its natural killer (NK) cell therapy ...